Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Okajima, Daisuke, Yasuda, Satoru, Maejima, Takanori, Karibe, Tsuyoshi, Sakurai, Ken, Aida, Tetsuo, Toki, Tadashi, Yamaguchi, Junko, Kitamura, Michiko, Kamei, Reiko, Fujitani, Tomomichi, Honda, Tomoyo, Shibutani, Tomoko, Muramatsu, Sumie, Nakada, Takashi, Goto, Riki, Takahashi, Shu, Yamaguchi, Miki, Hamada, Hirofumi, Noguchi, Yutaka, Murakami, Masato, Abe, Yuki, Agatsuma, Toshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398094/
https://www.ncbi.nlm.nih.gov/pubmed/34413126
http://dx.doi.org/10.1158/1535-7163.MCT-21-0206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398094/
https://www.ncbi.nlm.nih.gov/pubmed/34413126
http://dx.doi.org/10.1158/1535-7163.MCT-21-0206

Ejemplares similares